ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

DCBDC Board Ok’s New Initiative For Training

November 16, 1990

GM Corp, to Reimburse Marrow Transplants for Breast Cancer

March 15, 1996

NCI advisors approve recompetition of $62 million phase II contracts program.

November 19, 2004

After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA

April 14, 1995

Cancer Act 25th Year: cancer Mortality Rate Began decline In 1990s, NCI, ACS Studies Find

November 22, 1996

In Brief: UICC Honors Dodd; Centers Recognize Nealon; Tale Expands Transplant Program

March 28, 1997